- Home
- OTLK vs SCLX Comparison
OTLK vs SCLX Comparison
Compare OTLK & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- SCLX
- Stock Information
- Founded
- OTLK 2010
- SCLX 2011
- Country
- OTLK United States
- SCLX United States
- Employees
- OTLK N/A
- SCLX N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- OTLK Health Care
- SCLX Health Care
- Exchange
- OTLK Nasdaq
- SCLX Nasdaq
- Market Cap
- OTLK 56.3M
- SCLX 45.5M
- IPO Year
- OTLK 2016
- SCLX N/A
- Fundamental
- Price
- OTLK $1.48
- SCLX $0.29
- Analyst Decision
- OTLK Strong Buy
- SCLX Strong Buy
- Analyst Count
- OTLK 5
- SCLX 4
- Target Price
- OTLK $10.20
- SCLX $14.00
- AVG Volume (30 Days)
- OTLK 467.0K
- SCLX 1.5M
- Earning Date
- OTLK 02-14-2025
- SCLX 03-25-2025
- Dividend Yield
- OTLK N/A
- SCLX N/A
- EPS Growth
- OTLK N/A
- SCLX N/A
- EPS
- OTLK N/A
- SCLX N/A
- Revenue
- OTLK N/A
- SCLX $55,152,000.00
- Revenue This Year
- OTLK N/A
- SCLX $24.19
- Revenue Next Year
- OTLK $288.46
- SCLX $109.90
- P/E Ratio
- OTLK N/A
- SCLX N/A
- Revenue Growth
- OTLK N/A
- SCLX 22.02
- 52 Week Low
- OTLK $0.87
- SCLX $0.21
- 52 Week High
- OTLK $12.85
- SCLX $2.30
- Technical
- Relative Strength Index (RSI)
- OTLK 41.52
- SCLX 38.90
- Support Level
- OTLK $1.38
- SCLX $0.21
- Resistance Level
- OTLK $1.56
- SCLX $0.38
- Average True Range (ATR)
- OTLK 0.12
- SCLX 0.04
- MACD
- OTLK 0.02
- SCLX 0.01
- Stochastic Oscillator
- OTLK 59.26
- SCLX 43.56
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.